By the end of 2017, CTS has secured three source plasma partners and continues to seek additional partners in the plasma industry in order to continue to diversify CTS’s revenue stream.
In October, due to demand from existing healthcare partners, CTS began testing blood donors for anti...
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).